Mereo BioPharma Group plc ( MREO) Stock. Should you Buy or Sell? $ 1.07
0.06 (5.31 %)
Mereo BioPharma Group plc Analysis
Updated on 10-09-2022| Symbol | MREO |
| Price | $1.07 |
| Beta | 0.615 |
| Volume Avg. | $5.42 M |
| Market Cap | $125.17 M |
| 52 Week Range | $0.301 - $2.73 |
Mereo BioPharma Group plc opened the day at $1.07 which is +'5.31 % on yesterday's close. Mereo BioPharma Group plc has a 52 week high of $2.73 and 52 week low of $0.301, which is a difference of $2.429. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $125.17 M and total net profit is $36464000 which means the company is trading at 3.43 times profit to market capitalization. Theoretically, if you were to buy Mereo BioPharma Group plc for $125.17 M, it would take 15 years to get your money back. Mereo BioPharma Group plc are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Mereo BioPharma Group plc Stock Forecast - Is Mereo BioPharma Group plc a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Strong Sell | |
| DE Score | Strong Buy | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | 9.727 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Mereo BioPharma Group plc
| Price Book Value Ratio | 1.038 | Price To Book Ratio | 1.038 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -1.466 |
How liquid is Mereo BioPharma Group plc
| Current Ratio | 7.920 |
| Quick Ratio | 7.664 |
Debt
| Debt Ratio | 0.304 | Debt Equity Ratio | 0.437 |
| Long Term Debt To Capitalization | 0.155 | Total Debt To Capitalization | 0.160 |
Latest news about Mereo BioPharma Group plc
Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Consider these tips for making a penny stocks watchlist right now The post How to Make a Penny Stocks Watchlist in July 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.
Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AstraZeneca plc (NASDAQ: AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ: MREO), according to a report in The Times. The Times' report says that "Mereo would accept $5, equating to $500 million including American depositary receipts or ADRs.
About Mereo BioPharma Group plc
Description :
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
